汇宇制药9月15日获融资买入2550.87万元，融资余额2.08亿元

Group 1 - The core viewpoint of the news is that Huayu Pharmaceutical has experienced fluctuations in financing activities, with a notable net financing outflow on September 15, indicating potential investor caution [1] - On September 15, Huayu Pharmaceutical's stock price increased by 0.84%, with a trading volume of 187 million yuan, while the financing buy-in amount was 25.51 million yuan and the financing repayment was 35.92 million yuan, resulting in a net financing outflow of 10.41 million yuan [1] - As of September 15, the total balance of margin trading for Huayu Pharmaceutical was 208 million yuan, which represents 2.65% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of June 30, the number of shareholders for Huayu Pharmaceutical was 16,300, a decrease of 11.81% from the previous period, while the average circulating shares per person increased by 25.85% to 21,131 shares [2] - For the first half of 2025, Huayu Pharmaceutical reported a revenue of 453 million yuan, a year-on-year decrease of 14.86%, and a net profit attributable to shareholders of -80.72 million yuan, reflecting a significant year-on-year decline of 223.78% [2] - Since its A-share listing, Huayu Pharmaceutical has distributed a total of 474 million yuan in dividends, with 385 million yuan distributed over the past three years [2]